Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 2
2015 5
2016 3
2017 7
2018 6
2019 3
2020 3
2021 5
2022 6
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Sitbon O, et al. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. N Engl J Med. 2015. PMID: 26699168 Free article. Clinical Trial.
The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period (defined for each patient as 7 days after the date of the last intake of selexipag or placebo). RESULTS: A prima …
The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of …
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
Ogo T, Shimokawahara H, Kinoshita H, Sakao S, Abe K, Matoba S, Motoki H, Takama N, Ako J, Ikeda Y, Joho S, Maki H, Saeki T, Sugano T, Tsujino I, Yoshioka K, Shiota N, Tanaka S, Yamamoto C, Tanabe N, Tatsumi K; Study Group. Ogo T, et al. Eur Respir J. 2022 Jul 7;60(1):2101694. doi: 10.1183/13993003.01694-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 34824052 Free PMC article. Clinical Trial.
CONCLUSION: Selexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity remained unchanged. Further large-scale investigation is necessary to prove the role of selexipag in CTEPH....
CONCLUSION: Selexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity …
Selexipag in Patients With Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Qin J, Wang G, Han D. Qin J, et al. Curr Probl Cardiol. 2023 Feb;48(2):101466. doi: 10.1016/j.cpcardiol.2022.101466. Epub 2022 Oct 23. Curr Probl Cardiol. 2023. PMID: 36283497 Review.
Selexipag was safe and significantly improved hospitalization for worsening of PH, WHO FC, mPAP, NT-proBNP, and cardiac index in patients with PH. Selexipag should be considered in patients with pulmonary arterial hypertension or chronic thromboembolic PH....
Selexipag was safe and significantly improved hospitalization for worsening of PH, WHO FC, mPAP, NT-proBNP, and cardiac index in pati …
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Galiè N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Galiè N, et al. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30. Adv Ther. 2022. PMID: 34727317 Free PMC article. Clinical Trial.
RESULTS: Overall, 953 patients in GRIPHON and GRIPHON OL were treated with selexipag. At the time of selexipag initiation, 81.2% of patients were receiving background PAH therapy. ...A large proportion of the population was receiving background therapy at selexip …
RESULTS: Overall, 953 patients in GRIPHON and GRIPHON OL were treated with selexipag. At the time of selexipag initiation, 81. …
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, McLaughlin VV, Du Roure C, Rubin LJ, Sitbon O, Tapson V, Lang IM. Rosenkranz S, et al. Eur J Heart Fail. 2022 Jan;24(1):205-214. doi: 10.1002/ejhf.2369. Epub 2021 Nov 21. Eur J Heart Fail. 2022. PMID: 34806261 Free PMC article. Clinical Trial.
AIMS: The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH-targeted therapies in this population. These post hoc analyses explored the effect of selexipag in PAH patients with cardiovasc …
AIMS: The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response t …
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis.
Chen M, Lai Y, Chen R, Lu J, Zhang Y, Liu H, Wang D, Zhong Y, Zheng Z, Hong C. Chen M, et al. Pulm Pharmacol Ther. 2022 Feb;72:102100. doi: 10.1016/j.pupt.2021.102100. Epub 2021 Nov 29. Pulm Pharmacol Ther. 2022. PMID: 34856365 Review.
BACKGROUND AND OBJECTIVE: This meta-analysis was performed to evaluate the effect and safety of selexipag in the treatment of pulmonary hypertension and to explore the effect of selexipag on cardiac function indexes in PAH patients. ...Selexipag effectively r …
BACKGROUND AND OBJECTIVE: This meta-analysis was performed to evaluate the effect and safety of selexipag in the treatment of pulmona …
Selexipag for Chronic Thromboembolic Pulmonary Hypertension in Japanese Patients - A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase II Study.
Tanabe N, Fukuda K, Matsubara H, Nakanishi N, Tahara N, Ikeda S, Kishi T, Satoh T, Hirata KI, Inoue T, Kimura H, Okano Y, Okazaki O, Sata M, Tsujino I, Ueno S, Yamada N, Yao A, Kuriyama T. Tanabe N, et al. Circ J. 2020 Sep 25;84(10):1866-1874. doi: 10.1253/circj.CJ-20-0438. Epub 2020 Sep 3. Circ J. 2020. PMID: 32879152 Free article. Clinical Trial.
The selexipag group also showed improvement in total pulmonary resistance and cardiac index. CONCLUSIONS: Selexipag treatment improved pulmonary hemodynamics in Japanese patients with CTEPH, but PVR did not show a significant difference between the selexipag …
The selexipag group also showed improvement in total pulmonary resistance and cardiac index. CONCLUSIONS: Selexipag treatment …
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grünig E, Hoeper MM, Martin N, Mathai SC, McLaughlin VV, Perchenet L, Poch D, Saggar R, Simonneau G, Galiè N. Chin KM, et al. J Am Coll Cardiol. 2021 Oct 5;78(14):1393-1403. doi: 10.1016/j.jacc.2021.07.057. J Am Coll Cardiol. 2021. PMID: 34593120 Free article. Clinical Trial.
OBJECTIVES: TRITON (The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension; NCT02558231), a multicenter, double-blind, randomized phase 3b study, evaluated initial triple (macitentan, …
OBJECTIVES: TRITON (The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed …
Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).
Howard LS, Rosenkranz S, Frantz RP, Hemnes AR, Pfister T, Hsu Schmitz SF, Skåra H, Humbert M, Preston IR. Howard LS, et al. Chest. 2023 Feb;163(2):407-418. doi: 10.1016/j.chest.2022.08.2231. Epub 2022 Sep 8. Chest. 2023. PMID: 36089068 Free PMC article. Clinical Trial.
RESEARCH QUESTION: Can actigraphy be used to assess changes in DLPA in patients with PAH receiving selexipag or placebo? STUDY DESIGN AND METHODS: Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension (TRACE) was a pros …
RESEARCH QUESTION: Can actigraphy be used to assess changes in DLPA in patients with PAH receiving selexipag or placebo? STUDY DESIGN …
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N. Beghetti M, et al. Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11. Eur J Heart Fail. 2019. PMID: 30632656 Free PMC article. Clinical Trial.
The rate of the primary composite endpoint of morbidity/mortality was lower in patients with corrected CHD-PAH who were treated with selexipag compared with those treated with placebo (HR 0.58; 95% CI 0.25, 1.37). The most common adverse events were those known to be relat …
The rate of the primary composite endpoint of morbidity/mortality was lower in patients with corrected CHD-PAH who were treated with sele …
37 results

Searches related to "selexipag"